Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...

In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying e ...

Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...

In about 5–10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.